Corrigendum to “van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.” Kidney Int. 2020;97:202–212 (Kidney International (2020) 97(1) (202–212), (S0085253819309913), (10.1016/j.kint.2019.09.013))

E. J. M. van Bommel, M. H. A. Muskiet, M. J. B. van Baar

Research output: Contribution to journalComment/Letter to the editorAcademic

2 Citations (Scopus)


The authors regret an error in Supplementary Figure S1. Of patients treated with dapagliflozin, 24 were analyzed; of those treated with gliclazide, 20 were analyzed. The authors would like to apologize for any inconvenience caused.

Original languageEnglish
Pages (from-to)1061-1061
Number of pages1
JournalKidney International
Issue number5
Publication statusPublished - May 2020

Cite this